AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
REGULATORY UPDATE: FDA Releases HCT/P Guidance Documents Related to Donor Eligibility
January 07, 2025
REGULATORY UPDATE: FDA Releases 2025 Guidance Agenda
January 03, 2025
FDA Approves First MSC Therapy to Treat GvHD
January 02, 2025